MAPT and Alzheimer disease: In multiple AD mouse models with Aβ and Tau pathology, the enhancement of the ALP expression by exogenous TFEB has been demonstrated to significantly reduce Aβ and Tau pathological changes, improve cognitive impairment, upregulate PINK1, and enhance autophagy/mitophagy [30].